Story perspectives
Novo Nordisk Freezes Hiring Amid Weight-Loss Drug Competition
8/21/2025
50 8
1 of 1
Story summary
- Novo Nordisk implemented a hiring freeze due to heightened competition in the weight-loss medication sector, especially from Eli Lilly's Zepbound.
- The company's stock dropped 21.83%, leading to a profit warning.
- New CEO Mike Doustdar plans cost-saving measures and possible layoffs to tackle market pressures.
- Rising GLP-1 drug usage is contributing to increased employer health insurance costs.